The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
A major push to sharpen the future of cancer treatment is underway
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Highlights Mirvetuximab-based regimen promise
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The company says the platform offers improved manufacturability and functional advantages
Subscribe To Our Newsletter & Stay Updated
